Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
139 hedge funds and large institutions have $1.12B invested in Day One Biopharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 35 reducing their positions, and 17 closing their positions.
189% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $575K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
46% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 35
18% more capital invested
Capital invested by funds: $952M → $1.12B (+$171M)
7% more funds holding
Funds holding: 130 → 139 (+9)
0.81% less ownership
Funds ownership: 89.17% → 88.36% (-0.81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
+$23.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$10.6M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$6.35M |
| 4 |
Morgan Stanley
New York
|
+$6.19M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$6.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPX
Canaan Partners XI
Menlo Park,
California
|
-$30.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.9M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$22.9M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
151
Crewe Advisors
Salt Lake City,
Utah
| – | -$369 | -30 | Closed |
|
152
Osaic Holdings
Scottsdale,
Arizona
| – | -$294 | -24 | Closed |
|
153
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$184 | -15 | Closed |
|
|
C
154
Covestor
London,
United Kingdom
| – | -$12 | -1 | -11% |
|
DAWN Hedge Fund Activity: Q4 2023 in Review
139 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2023, worth a combined $1.12B — up 18% from $952M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new DAWN positions and 17 closed out — a net gain of 9 holders — while 51 added to existing stakes and 35 trimmed.
The largest buyer was Pictet Asset Management, adding an estimated $23.9M. The largest seller was Canaan Partners XI, exiting entirely with an estimated $30.2M sold.
- 139 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2023, up from 130 in Q3 2023.
- Funds reported $1.12B of Day One Biopharmaceuticals stock for Q4 2023, up 18% quarter-over-quarter.
- 26 funds opened new Day One Biopharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +9 holders.
- The largest Day One Biopharmaceuticals buyer in Q4 2023 was Pictet Asset Management, an estimated $23.9M added.
- The largest Day One Biopharmaceuticals seller in Q4 2023 was Canaan Partners XI, an estimated $30.2M sold.
Based on aggregated 13F filings for Q4 2023.